Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 129   

Articles published

NVO 47.75 +0.22 (0.46%)
price chart
CHMP Gives Positive Opinion On Novo Nordisk's Obesity Drug Saxenda
Yesterday Novo Nordisk A/S (ADR) (NYSE:NVO) said that it has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP), for its obesity drug Saxenda.
Novo Nordisk receives positive opinion from the European regulatory ...  Nasdaq
Price Target Update on Novo Nordisk A/S (ADR)
Novo Nordisk A/S (ADR) (NYSE:NVO): The mean short term price target for Novo Nordisk A/S (ADR) (NYSE:NVO) has been established at $58.52 per share.
High Conviction Stock Picks - Colgate-Palmolive Co. (NYSE:CL), Novo Nordisk ...  Wall Street Observer
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate ...
Novo Nordisk A/S (ADR) (NYSE:NVO) also kept its spot in Mr. Simons' list. The $189 billion market cap healthcare company witnessed a 5% boost in the fund's exposure between April and June.
Novo Nordisk To Go Ahead With Russian Investment
The world's largest insulin-maker, Novo Nordisk A/S (ADR) (NYSE:NVO) is going ahead with its investment plans for Russia, even after the ruble's drastic fall.
Stocks Underperform for the Week: Novo Nordisk A/S , Cablevision Systems Corp  Ashburn Daily
Novo Nordisk's (NVO) Diabetes Drug Victoza Receives Positive Review By CHMP
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Friday that its key drug Victoza has received positive reviews from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes ...
Related articles »  
Novo Nordisk A/S (ADR) (NVO): A Company Solving The Global Diabetes Crisis ...
Novo Nordisk A/S (NYSE: NVO) is the undisputed global leader in the diabetes market. The company's impressive product portfolio is home to five of the world's 10 best-selling diabetes medications.
Related articles »  
Is Novo Nordisk A/S (ADR) (NVO) Going to Burn These Hedge Funds?
Out of the hedge funds we follow, Renaissance Technologies, managed by Jim Simons, holds the largest position in Novo Nordisk A/S (ADR) (NYSE:NVO). Renaissance Technologies has a $433.1 million position in the stock, comprising 1.1% of its 13F ...
Related articles »  
Trading Insights on Novo Nordisk A/S (NYSE:NVO)
[ZACKS]Novo Nordisk A/S (ADR) (NYSE:NVO) announced that the company will first launch its combination diabetes drug, Xultophy, in Switzerland.
Novo Nordisk A/S (ADR) Receives Average Target Price of $56.66  Rock Hill Daily
Swedbank Lowers Novo Nordisk A/S to Reduce (NVO)  Dakota Financial News
Novo Nordisk (NVO) Wins FDA Nod For Weight-Loss Injection
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Wednesday that the US Food and Drug Administration (FDA) has approved its experimental weight-loss injection, Saxenda, to treat obesity in adults.
Related articles »  
Novo Nordisk And Eli Lilly Battling To Win GLP-1 Drug Market
Novo Nordisk A/S (ADR) (NVO) is currently leading the GLP-1 agonist space with its injectable drug Victoza, which was launched in 2009.
Related articles »